AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
2 days ago · THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data. "As previously stated, Amgen does not see an association between the administration of MariTide and bone mineral density changes. The Phase 1 study results do not suggest any bone safety concern or change our ...
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
1 day ago · Published. Nov 13, 2024 5:00am EST. THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly ...
Amgen Defends Its Investigational Monthly Weight Loss Injection …
1 day ago · On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. On Wednesday, Amgen Inc ...
A scrap of data on Amgen's obesity drug MariTide wipes out …
2 days ago · Nov. 12, 2024. National Biotech Reporter. On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value. The data, spotted by an ...
Amgen MariTide bone mineral density loss data ‘leaked,’ says …
3 days ago · Nov. 12, 2024, 01:30 PM. Cantor Fitzgerald tells investors that MariTide’s Phase 1 data includes “a big surprise” as the supplemental appendix file seems to show bone mineral density, or BMD ...
Amgen axes an obesity asset, zooms in on MariTide - Fierce Biotech
May 2, 2024 · MariTide, a GIPR antagonist conjugated to two GLP-1 analogues, now stands in the limelight. The obesity candidate, previously dubbed AMG 133, is currently being assessed in a phase 2 dose-ranging...
Amgen obesity drug MariTide: four key questions going forward
May 3, 2024 · The injectable drug MariTide, designed to be given monthly, could be a more attractive option than Wegovy and Zepbound, which are both dosed weekly.
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
2 days ago · November 13, 2024. Amgen (NASDAQ: AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data. "As previously stated, Amgen does not see an ...
Amgen dismisses bone density concerns related to its weight-loss …
1 day ago · The drugmaker's stock slumped 7% on Tuesday after analysts at Cantor Fitzgerald said their review of early-stage data on Amgen's MariTide showed a drop in bone mineral density, which can increase ...
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
1 day ago · Share this article. THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase ...
- Some results have been removed